Product Overview
Blend: Semaglutide + Tirzepatide combination (“Semacagri TRE Blend”)
Format: Lyophilized powder, standard research vial
For research use only—NOT for human or veterinary use.
Each batch is third‑party tested for identity and purity. COAs available on request—email providers@theratideusa.com.
This dual-action blend combines a GLP‑1 receptor agonist (semaglutide) with a GIP/GLP‑1 receptor co-agonist (tirzepatide):
- Tirzepatide vs Semaglutide: In a 72-week obesity study, tirzepatide (10–15 mg weekly) achieved ~20.2% weight loss vs ~13.7% with semaglutide (~2.4 mg weekly) :contentReference[oaicite:1]{index=1}.
- Clinical effectiveness: Tirzepatide consistently outperforms semaglutide both in glycemic control and weight loss across multiple trials :contentReference[oaicite:2]{index=2}.
- Mechanism of action: Semaglutide works via GLP‑1 pathways; tirzepatide additionally stimulates GIP receptors for enhanced insulin secretion and appetite suppression :contentReference[oaicite:3]{index=3}.
These clinical results support the rationale behind combining both molecules to potentially amplify metabolic benefits.
Why blend semaglutide and tirzepatide?
Combining GLP‑1 and GIP agonism can enhance weight loss and insulin sensitivity vs GLP‑1 alone.
Is one component stronger?
Tirzepatide alone has shown ~20% weight loss at high dose, outperforming semaglutide (~13.7%) over the same period :contentReference[oaicite:4]{index=4}.
What side effects may occur?
Clinical trials of both drugs report GI events: nausea, diarrhea, constipation; severe events are rare :contentReference[oaicite:5]{index=5}.
For research use only—not for human or veterinary use, nor as a dietary supplement. Please refer to our Terms & Conditions.
Safety Note: Handle within appropriate lab protocols and keep out of unauthorized access.
FDA Notice: These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
